Cubist Pharmaceuticals
Defunct American pharmaceutical company
From Wikipedia, the free encyclopedia
Cubist Pharmaceuticals, Inc. was an American biopharmaceutical company that targeted pathogens like MRSA.
| |
| Type | Subsidiary |
|---|---|
| Nasdaq: CBST | |
| Industry | Pharmaceuticals (Biopharmaceuticals & Biotherapeutics) |
| Founded | 1992 |
| Defunct | 2015 |
| Headquarters | Lexington, Massachusetts |
| Key people | Robert J. Perez (president & CEO) |
| Products | Product Pipeline |
| Revenue |  $926.4 million USD (2012) |
| Parent | Merck & Co. |
| Website | www.cubist.com |
.[1] The company employed 638 people, mostly in Lexington, Massachusetts.[2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).[3]
History
Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors.[4] Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.[5]
In 2011, the company acquired Adolor, maker of a drug for treatment of constipation.[6]
In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion.[7]
In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015.[8]
In January 2015, Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.[9][10]
Products
The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with Teva Pharmaceutical Industries regarding Cubicin.[11] In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium-fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year).[12]
In 2011, its product pipeline focused on gram-negative bacterial infections,[13] Clostridioides difficile infection,[14] and respiratory syncytial virus.[15]
Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.[16][17]